Novel therapies, risk pathways and prevention of mood disorders

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1059660

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Concordant with the NHMRC priorities, this fellowship will principally focus on the development of novel therapies for mood disorders. We have pilot data that the amino acid, N acetyl cysteine reduces symptoms in unipolar and bipolar disorder and schizophrenia. We will further delineate the spectrum of efficacy, mechanisms of action and tolerability profile of this and related agents. We also will study risk factors and pathways for the development of depression, to develop public health strategies.

Funded Activity Details

Start Date: 01-01-2014

End Date: 01-01-2018

Funding Scheme: Research Fellowships

Funding Amount: $863,413.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Psychiatry (incl. Psychotherapy)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

biomarkers | bipolar disorder | depression | novel therapies | prevention | risk factors

Related Links